II2 Stock Chart & Stats
€0.52
€0.00(0.00%)
At close: 4:00 PM EDT
€0.52
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.47 - €2.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€35.79M
Enterprise Value€31.87
Total Cash (Recent Filing)€30.42M
Total Debt (Recent Filing)€1.97M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Nov 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding46,489,117
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.85Price Target Upside448.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.52
Revenue Forecast (FY)€8.96M
Bulls Say, Bears Say
Bulls Say
International Revenue GrowthInternational growth despite the U.S. commercial pause indicates continued physician adoption and demand for CGuard in overseas markets. This geographic traction can diversify revenue and provide a foundation for broader expansion as U.S. products return to market.
Clinical And Regulatory PipelineStrong pivotal-trial outcomes and constructive FDA engagement support the potential approval of Prime 80 and other platforms. Regulatory progress could expand the addressable market, strengthen the carotid product portfolio and improve long-term commercial competitiveness.
Low Financial Leverage And Cost DisciplineLow debt limits fixed financial obligations, while the planned workforce reduction should lower the operating cost base. Together, these actions may preserve flexibility and extend runway while management funds regulatory work and prepares for commercial relaunch.
Bears Say
Severe Cash BurnPersistent negative operating and free cash flow means the business is not self-funding. Continued clinical, regulatory and commercial spending could require additional financing before approvals generate meaningful revenue, creating liquidity and potential dilution risk.
Deep Operating LossesThe company remains far from breakeven, with expenses vastly exceeding its small revenue base and gross margin only about 18% TTM. Sustained losses limit the durability of current operations and make successful product launches essential to future viability.
Recall And Regulatory Execution RiskThe recall disrupted U.S. sales and damaged reported gross profit, while redesign, biocompatibility testing and FDA timing delay the return of key products. Prolonged execution or regulatory setbacks could defer market access and increase cash needs.
InspireMD News
II2 FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was €0.47 and its highest was €2.06 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is €35.79M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Aug 17, 2026. The company reported -€0.147 earnings per share for the quarter, beating the consensus estimate of -€0.173 by €0.026.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.13.
How many shares outstanding does InspireMD have?
InspireMD has 46,489,117 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -€0.147 in its last earnings report, beating expectations of -€0.173. Following the earnings report the stock price went up 6.107%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in DE:II2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€2.85 (448.90% Upside)
€2.85 (448.90% Upside)
Blogger Sentiment
Neutral
DE:II2 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €148.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.89%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
II2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of encouraging operational and regulatory progress (21% international revenue growth, constructive FDA interactions, multiple potential approvals, enrollment in a pivotal SwitchGuard study, and planned annualized cost savings of ~$9 million) alongside significant near‑term challenges (voluntary recall driving $734k in customer credits and a $612k inventory impairment, a swing to negative GAAP gross margin, a wider net loss of $14.3M, and a substantial cash decline from $54.2M to $30.4M). Management articulated a clear remediation and relaunch plan and emphasized underlying demand, but financial impacts and regulatory timing risk keep the outlook balanced between opportunity and near‑term execution/liquidity challenges.View all DE:II2 earnings summariesII2 Stock 12 Month Forecast
Average Price Target
€2.85
▲(448.90% Upside)